KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) FCF Margin (2016 - 2025)

Nektar Therapeutics has reported FCF Margin over the past 16 years, most recently at 297.96% for Q4 2025.

  • Quarterly results put FCF Margin at 297.96% for Q4 2025, down 13808.0% from a year ago — trailing twelve months through Dec 2025 was 377.83% (down 19782.0% YoY), and the annual figure for FY2025 was 377.83%, down 19782.0%.
  • FCF Margin for Q4 2025 was 297.96% at Nektar Therapeutics, up from 414.55% in the prior quarter.
  • Over the last five years, FCF Margin for NKTR hit a ceiling of 159.88% in Q4 2024 and a floor of 629.51% in Q4 2021.
  • Median FCF Margin over the past 5 years was 301.09% (2025), compared with a mean of 310.8%.
  • Biggest five-year swings in FCF Margin: soared 36517bps in 2022 and later crashed -24832bps in 2025.
  • Nektar Therapeutics' FCF Margin stood at 629.51% in 2021, then soared by 58bps to 264.34% in 2022, then grew by 25bps to 197.97% in 2023, then rose by 19bps to 159.88% in 2024, then tumbled by -86bps to 297.96% in 2025.
  • The last three reported values for FCF Margin were 297.96% (Q4 2025), 414.55% (Q3 2025), and 409.62% (Q2 2025) per Business Quant data.